Desa(Desloratadine)

Quick links

Choose a section

Quick links to important sections

Advertisements

Desa(Desloratadine)

Advertisements
Advertisements

Overview of Desa(Desloratadine)

Property Description
Active Ingredient Desloratadine
Form Tablet, Syrup, Oral Disintegrating Tablet (ODT)
Pharmacological Class Second-Generation Antihistamine
General Purpose Provides relief from allergic symptoms
Origin Synthetic Derivative (Active Metabolite of Loratadine)

Defining Desloratadine: Second-Generation Antihistamine Classification

Desloratadine is the internationally recognized non-proprietary name (INN) for a single-ingredient product classified as a Second-Generation Antihistamine. It is a synthetic derivative that operates as the major active metabolite of the older antihistamine, Loratadine. This chemical composition is clinically recognized for providing effective relief while minimizing interaction with the central nervous system, leading to its key characteristic of being non-sedating. Desloratadine is included in the classification of systemic antihistamines, underscoring its established place in therapeutic practice.


Forms and General Therapeutic Purpose

The active compound, Desloratadine, is formulated for systemic oral administration and is comprised solely of the active ingredient, combined with various pharmaceutical excipients. Desloratadine is available in several dosage form(s), including the standard Tablet, a liquid Syrup often used for the pediatric population, and sometimes an Oral Disintegrating Tablet (ODT). The availability of a Syrup highlights a distinctive feature of the formulation, ensuring flexibility in delivery for patient groups who may have difficulty swallowing solid medication.

The general therapeutic purpose of the medication is to mitigate the effects of histamine released during an allergic response. The drug achieves this by performing selective H₁-receptor blockade, stabilizing the body's reaction to allergens. This action delivers a direct anti-allergic benefit and secondary anti-inflammatory support.

Advertisements

What side effects are possible with Desa(Desloratadine)?

Possible side effects and safety information

The safety profile for Desloratadine is officially structured by the frequency of adverse reactions observed in clinical use and post-marketing surveillance, classified by System Organ Class (SOC).

Common Adverse Reactions

In clinical trials involving adolescents and adults, the most frequently reported adverse reactions, documented as common, include headache, fatigue (asthenia), and dry mouth. Other effects observed at similar frequencies in regulatory documentation include pharyngitis and muscle pain (myalgia).


Serious and Very Rare Adverse Reactions

The official safety documents record very rare and clinically significant adverse reactions identified primarily through post-marketing reports, including severe hypersensitivity reactions such as anaphylaxis and angioedema. Other very rare events noted across various body systems include seizures and effects on the liver (hepatitis, increased liver enzymes) and heart (tachycardia, palpitations, QT prolongation).


Population-Specific Safety Considerations

The regulatory profile highlights specific considerations for certain patient groups. Individuals with renal or hepatic impairment may experience increased plasma concentrations of the medicine, which is a key note for dose selection. For the pediatric population (specifically children 6 to 23 months), adverse events reported at an incidence greater than placebo include diarrhoea, fever, and insomnia. Caution in dose selection is also noted for older adults.


Safety Restrictions

Desloratadine is contraindicated in patients with known hypersensitivity to the drug, to any of its excipients, or to Loratadine. Furthermore, the official labeling for Oral Disintegrating Tablets (ODT) contains a restriction note regarding the presence of aspartame, which is relevant for patients with Phenylketonuria (PKU).

Advertisements

Overdose and Emergency Response

Overdose and when to seek help for Desa (Desloratadine)

Official regulatory information describes the clinical presentation of Desloratadine overdose as an exaggeration of known adverse effects. These commonly documented manifestations include increased fatigue, somnolence (drowsiness), and headache.

Potential Severe Outcomes and Required Actions

While the signs may resemble common side effects, post-marketing reports indicate the potential for serious, high-magnitude effects that require immediate medical attention. These include cardiovascular events like tachycardia and palpitations, as well as central nervous system effects such as seizures and psychomotor hyperactivity.

Overdose Component Regulatory Status
Antidote Availability No specific antidote is available.
Dialysis Effectiveness Not eliminated by haemodialysis.
Pediatric Consideration Magnitude of effects can be higher in the pediatric population.

When to Seek Immediate Medical Help

Immediate medical attention is required for any suspected accidental overdose of Desloratadine. You must contact a Poison Control Center or emergency services right away. Seek urgent help if the person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Management is strictly based on symptomatic and supportive treatment, including standard measures to remove any unabsorbed substance, as Desloratadine is not effectively removed by dialysis.

Advertisements

Therapeutic Uses of Desa(Desloratadine)

What Desa(Desloratadine) treats: Main Uses and Benefits

Desloratadine is commonly used across domains involving certain distressing symptoms from allergies. It is relevant in contexts where additional symptomatic support is needed to address bothersome manifestations of an allergic response.

Desloratadine is commonly used to help with symptoms associated with allergic rhinitis (both seasonal and perennial) and chronic idiopathic urticaria (hives). Applied in settings marked by temporary physiological imbalance, it helps address symptom clusters that may become intense or disruptive, such as persistent sneezing, nasal congestion, runny nose, itchy eyes, and intense dermal pruritus. This provides support that helps ease the overall symptom burden.

Desloratadine may be part of symptomatic management by offering prolonged symptomatic relief across relevant domains, assisting with maintaining functional stability and supporting the patient during difficult episodes.

“This medication is applied in addressing recurrent or episodic manifestations where symptoms create noticeable functional strain.”


Quick Fact: Support for Common Allergic Symptoms Desloratadine is relevant for easing symptoms related to inflammatory or irritative states, often used during phases when heightened symptoms become more noticeable, particularly the intense skin itching and the bothersome combination of nasal and ocular discomfort.

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Eligibility Profile for Desloratadine


Who Must Not Use (Contraindicated)

Desloratadine is contraindicated for any patient with a known hypersensitivity to the active ingredient, to its precursor loratadine, or to any component of the specific formulation. Individuals with rare hereditary issues like galactose intolerance should avoid tablet formulations containing lactose.

Age and Developmental Status

Use is established for adults and adolescents (12 years of age and older). The minimum approved age is 6 months for the oral solution formulation. The medicine is not recommended for infants younger than six months, as official safety and efficacy have not been established in this age group.

Conditional Use and Restrictions

Patients with severe renal impairment or hepatic impairment require caution, as regulatory documents recommend a dosage modification due to pharmacokinetic changes that increase drug exposure. Use is also advised with caution in patients with a history of seizures. During pregnancy and lactation, use is generally not recommended; the drug passes into breast milk, requiring a decision to discontinue nursing or discontinue the medication.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Desloratadine centers on pharmacokinetic interactions that lead to increased systemic exposure. The primary prescribing labels do not list any formal contraindications based on drug–drug interactions; contraindications are limited to hypersensitivity to Desloratadine or Loratadine.

Documented Exposure-Modifying Agents

Co-administration with several medicinal products is documented to increase the plasma concentrations (Cmax and AUC) of both Desloratadine and its active metabolite, 3-hydroxydesloratadine. These include the antifungal Ketoconazole, the macrolide antibiotic Erythromycin, the H₂-receptor antagonist Cimetidine, the SSRI Fluoxetine, and the antibiotic Azithromycin.

Substance and Population Considerations

  • Food/Meal: Regulatory documents confirm that Desloratadine may be taken with or without a meal as no clinically relevant interaction with food is documented.
  • Alcohol (Ethanol): Clinical trials reported no potentiation of the performance-impairing effects of alcohol. However, post-marketing surveillance includes documented reports of alcohol intolerance and intoxication.
  • Population Exposure Risk: Patient populations with severe renal impairment or hepatic impairment exhibit significantly increased systemic exposure, which is an intrinsic factor of the drug's pharmacokinetics.
Advertisements

Mechanism of Action

Selective Histamine H₁ Receptor Antagonism

Desloratadine operates primarily as a long-acting, non-sedating antagonist of the peripheral H₁ histamine receptor. The core mechanism involves binding to the H₁ receptor, thereby preventing the endogenous inflammatory mediator, histamine, from engaging the receptor and activating its associated downstream signaling cascade. This receptor-mediated signaling blockade limits the impact of histamine's H₁-mediated activity, resulting in a modulation of downstream physiological responses.


Modulation of Pro-Inflammatory Signaling

Beyond its H₁ antagonism, Desloratadine influences multiple inflammatory signaling pathways. The compound modulates cellular activity by inhibiting the release of certain pro-inflammatory mediators from mast cells and basophils, and by suppressing the production of specific cytokines, including IL-4, IL-6, IL-8, and IL-13. This modulation acts on early molecular steps that influence systemic physiological outcomes by supporting a regulated state within targeted pathways.


Effect on Vascular Signaling Pathways

The combined direct and indirect mechanistic effects influence biological systems where these specific transmitters and mediators dominate. By modifying the signaling sequences subsequent to H₁ receptor inhibition and inflammatory mediator suppression, the drug affects intracellular processes that often lead to changes in vascular permeability and vasodilation. This action promotes a modulation of pathway activity, particularly concerning the signaling that regulates vascular tone.

Advertisements

Dosage and Administration Information

How to Use Desloratadine: Official Administration Guidelines

Desloratadine is approved for oral systemic administration in several forms, including film-coated tablets, an oral solution, and oral disintegrating tablets (ODT). The official administration guidelines standardize the dosing and timing, while also detailing necessary adjustments for specific physiological conditions.


Official Dosing and Use Patterns

The standard approach to Desloratadine use is based on a once-daily regimen, simplifying the intake schedule.

Population Group Standard Daily Dose Frequency Special Conditions
Adults & Adolescents (ge 12 years) 5 mg Once Daily May be taken with or without food.
Children 6 to 11 years 2.5 mg Once Daily Dose administered via tablet or oral solution.
Children 6 months to 5 years 1.0 mg – 1.25 mg Once Daily Dose administered via oral solution.
Hepatic/Renal Impairment 5 mg Every Other Day Frequency adjustment required to prevent accumulation.

Administration Context and Duration

The timing of Desloratadine intake is flexible; it can be administered with or without food. For the oral solution, a calibrated dosing device must be used to ensure correct measurement, particularly for pediatric patients. Oral Disintegrating Tablets are placed on the tongue to rapidly dissolve and are swallowed immediately upon removal from the packaging.

Regarding the duration of use, the labeled instructions specify two patterns: treatment may be intermittent for recurrent, temporary symptoms, or it can be continued long-term for persistent conditions such as chronic urticaria, maintaining the standard once-daily schedule.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Desloratadine

Evidence for Use in Allergic Rhinitis and Symptom Relief

The clinical evidence for desloratadine is based on randomized, double-blind, placebo-controlled multicenter trials that examined short-term changes in allergic rhinitis (AR), including seasonal and perennial forms. Researchers evaluated outcomes related to physical discomfort, such as Total Symptom Scores (TSS), sneezing, and watery discharge. Studies also monitored patient-reported outcomes describing perceived discomfort and functional status, including quality of life. Research explored objective changes, such as nasal airflow, and examined measurements of certain inflammatory biomarkers to provide context on symptom evolution.

Evidence for Use in Chronic Idiopathic Urticaria (Hives)

For chronic idiopathic urticaria (hives), desloratadine was evaluated in controlled trials, typically up to six weeks. The primary outcomes studied were specific measurements of physical discomfort, focusing on the reported severity of itching (pruritus) and the size and number of wheals (hives). Research also explored functional outcomes, monitoring interference with sleep and daily activities caused by the condition.

Evidence in Special Populations and Long-Term Research

Specific research has examined desloratadine in pediatric populations (children aged two to twelve years) for both AR and CIU. Findings describe patterns observed in these specific populations, but results apply only to the populations studied. The primary evidence for both conditions was evaluated in short-term trials where follow-up durations were limited.

What Remains Uncertain in the Research Landscape

Evidence highlights that a key area where certainty remains low is in the long-term effects beyond the initial controlled trials; long-term effects are not fully established by controlled research designs. Data regarding longer-term patterns of symptom change primarily stems from observational settings. Furthermore, while controlled research against placebo is available, comparative evidence against other similar medicines is limited in certain patient subgroups. Research provides context but does not determine whether an individual will respond similarly.

Key Studies & References Desloratadine (Oral Route) - MedlinePlus Drug Information

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Desa(Desloratadine) (FAQ)

Q: What is the main difference between Desa and Loratadine (Claritin)?

Official information indicates that Desloratadine is the major active metabolite of Loratadine. This difference in chemical structure results in Desloratadine having a longer half-life, which supports its sustained 24-hour efficacy. Clinical evidence also suggests Desloratadine may modulate inflammatory signaling pathways.

Q: Is Desa considered a steroid?

No. Desloratadine is categorized by major regulatory bodies as a long-acting tricyclic histamine antagonist, which is a type of antihistamine. It is not classified as a steroid medication.

Q: Does Desa cause weight gain?

Regulatory safety documents include post-marketing reports of adverse events such as increased appetite and weight increased. As these reports are classified as having an unknown frequency, regulatory data cannot provide a reliable estimate of how often these events occur.

Q: Does Desa interact with common painkillers like ibuprofen?

The primary regulatory documents and prescribing labels do not list a specific, clinically relevant interaction between desloratadine and common over-the-counter non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen.

Q: How quickly does Desa start to work after taking it?

Clinical studies show that the antihistaminic effects of Desloratadine are reported to occur within 1 hour following administration. The reported onset of action supports its utility in relieving symptoms promptly.

Q: What happens if I accidentally take a dose of Desa twice?

Official patient information states that in the event of suspected overdosage (taking too much of the medicine), official guidance recommends contacting a poison control center or seeking emergency medical assistance.

Q: Is it safe to drink coffee while taking Desa?

Official product information states that Desloratadine may be taken with or without food or drink. No clinically relevant interactions with general consumption, including common beverages like coffee, are documented in regulatory information.

Q: Does Desa lose its effectiveness over time (tolerance)?

Clinical studies examined the drug's long-term effect and found no evidence of tachyphylaxis (rapid loss of response or tolerance) over a 28-day continuous treatment period.

Q: Is Desa the same drug as Clarinex?

Desloratadine is the active ingredient found in the brand-name medicine Clarinex in some regions. It is also available globally in various generic formulations.

Q: What if I forget to take a dose of Desa—should I just wait for the next one?

Official guidance indicates that if a dose is missed, it can be taken as soon as the patient remembers. If it is almost time for the next scheduled dose, the missed dose should be skipped to continue the regular schedule. It is specified that a double dose should not be taken to compensate for the missed dose.

Q: Can Desa cause anxiety or nervousness?

Official reports from clinical trials have listed nervousness and psychomotor hyperactivity as observed adverse reactions in some patients. Patients are encouraged to report any unexpected reactions to their healthcare provider.

Q: Why might a doctor prescribe Desa instead of a different antihistamine?

Regulatory documents describe Desloratadine’s distinct characteristics, such as its long duration of effect (24 hours), its classification as a non-sedating medicine, and evidence supporting additional anti-inflammatory properties beyond simple histamine blockade. These properties provide the factual basis for its selection.

Q: Does Desa impact birth control pills?

Regulatory documents and official interaction studies do not currently list a specific clinical interaction between Desloratadine and oral contraceptives (birth control pills).

Q: How long does the effect of one dose of Desa usually last?

Studies report that the antihistaminic effects of one dose persist for up to 24 hours. This duration supports the once-daily dosing regimen outlined in the official administration guidelines.

Q: Can Desa be taken with certain stomach medicines (antacids)?

Official prescribing information does not list a specific interaction between Desloratadine and common stomach medicines, such as antacids.

Q: Is Desa commonly used in other countries under different names?

Yes, Desloratadine is the international active ingredient name. It is marketed globally under various brand names, such as Clarinex in the U.S. and numerous generic and local brand names across Europe and other regions.

Q: Does Desa cause any issues with driving or operating machinery?

While Desloratadine is categorized as a non-sedating medicine, regulatory guidance notes that drowsiness may very rarely occur. Therefore, official guidance recommends that individuals ensure they are not affected by drowsiness before performing activities that require full attention, such as driving or operating machinery.

Q: Is a prescription always required for Desa?

In the U.S. and many European countries, Desloratadine is typically classified as a prescription medicine (Rx only). Its regulatory status may vary by country or specific dose strength.

Q: Does Desa affect sleep, even if it's considered non-drowsy?

Although Desloratadine is classified as non-sedating, official reports from clinical trials have listed both insomnia (difficulty sleeping) and somnolence (drowsiness) as adverse reactions observed in some patients.

Q: Does Desa help with eye itchiness or just sneezing?

Yes. Official product monographs indicate that Desloratadine is intended for the fast, 24-hour relief of both nasal and non-nasal symptoms. This includes relief of symptoms like itching of the eyes (ocular pruritus).

Q: Can taking Desa make my other chronic condition worse?

Regulatory documents list specific chronic conditions that require caution or dose adjustment. This includes patients with asthma, a history of seizures, or with pre-existing renal or hepatic impairment.

Q: Does Desa contain lactose or gluten?

Official excipient lists show that Desloratadine tablet formulations commonly contain lactose as an inactive ingredient. Regulatory documents do not generally list gluten, which typically indicates it is not present in the formulation.

Advertisements

How should Desa(Desloratadine) be stored and disposed of?

Storage and Disposal of Desa (Desloratadine)

The storage and disposal of Desloratadine must adhere to regulatory requirements to ensure product quality and safety.


Official Storage Conditions

Constraint Requirement
Temperature Store at or below 30 °C (86 °F). Keep from freezing.
Protection Keep in the original package to protect from moisture and light.
Stability Tablets in containers may have a 3-month stability limit after first opening.
Child Safety Store out of the sight and reach of children.

Disposal Instructions

Official guidelines state Do not throw away any medicines via wastewater or household waste. Unused or expired medication must be disposed of in accordance with local regulations. Patients should consult a pharmacist for guidance on proper drug disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Desa(Desloratadine) found in:

A-Z Index: